



For further information, please contact:

Gene Logic Inc.

Robert G. Burrows (investors/media)
Director, Corporate Communications
301.987.1824
Email: rburrows@genelogic.com

Gene Logic Inc.

Philip L. Rohrer, Jr. (investors)
Chief Financial Officer
301.987.1700
Email: prohrer@genelogic.com

Gene Logic Reports First Quarter 2002 Results

*— Revenues Increase 44%, Loss Narrows,
and GeneExpress® Products Sales Growth Highlight Quarter —*

GAITHERSBURG, Md.—April 29, 2002—Gene Logic Inc. (Nasdaq: GLGC), a leading provider of integrated genomics information and bioinformatics products and services, reported its financial results for the first quarter of 2002.

Revenue for the first quarter of 2002 was \$11.8 million, an increase of 44% when compared to the first quarter of 2001. The increase in total revenue during the first quarter of 2002, versus the comparable period of 2001, was primarily the result of additional subscriptions to and purchases of GeneExpress® products and services.

For the first quarter of 2002, Gene Logic reported a net loss of \$7.5 million, or \$0.28 per share, compared to a net loss of \$10.6 million, or \$0.40 per share, for the same period of 2001, an improvement of 29% and \$0.12 per share, respectively. This improvement is the result of a \$3.6 million increase in revenue and an \$0.8 million reduction in operating expenses, partially offset by a shortfall in net interest income of \$2.4 million, or \$0.09 per share.

Commenting on the first quarter results, Philip L. Rohrer, Jr., Chief Financial Officer of Gene Logic stated, “We are pleased with our results for the quarter. Our results continue to confirm our commercial and operational success. Revenue for this quarter represents the 13th consecutive quarter in which quarterly revenue, compared to quarterly revenue a year before, grew by at least 25%.”

First Quarter 2002 Highlights

■ Growth of GeneExpress® Business:

- Takeda Chemical subscribed to a custom GeneExpress® product, which included access to ToxExpress™ and to a CustomSuite product.
- Daiichi Pharmaceuticals subscribed to BioExpress™.
- Morphochem AG subscribed to the GeneExpress® Oncology DataSuite™ and will purchase a series of GeneExpress® Reports.
- Artesian Therapeutics subscribed to the GeneExpress® Cardiovascular DataSuite™.

■ Growth of GeneExpress® Reports Business:

-- During the first quarter of 2002, the following biotechnology companies signed agreements to purchase GeneExpress® Reports: DGI Biotechnologies, Morphochem AG, DirectGene, GlycoDesign, Xantos Biomedicine AG and Cell Therapeutics.

■ GeneExpress® Products:

-- The GeneExpress® Central Nervous System (CNS) DataSuite™, which is a by-product of Gene Logic's CNS Program focused on psychiatric and neurodegenerative indications, was launched in February 2002 at the Genome Tri Conference.

-- The Company discussed new predictive modeling capabilities for early toxicity screening within its ToxExpress™ Program at the Society of Toxicology Annual Meeting.

Q1 2002 Results Conference Call Information

Investors may listen to Gene Logic's senior management discuss the details of this announcement during a conference call scheduled for Monday, April 29, 2002 at 10:00 a.m. Eastern by dialing: domestic – 800/699-8358; or international – 706/679-5588. No passcode is required for the live call. A replay of the call will be available through Monday, May 13, 2002 by dialing: domestic – 800/642-1687; or international – 706/645-9291. The passcode for the replay will be 3579132. A Webcast of the call will also be available for live participation accessed at www.companyboardroom.com or on the Gene Logic Web site – www.genelogic.com. A replay of the Webcast will be available until June 1, 2002.

Gene Logic Overview

Gene Logic Inc. is a leading provider of integrated genomics information and bioinformatics products and services related to gene activity in human disease and toxicity that enable global pharmaceutical and biotechnology companies to optimize the time, risk and cost of drug discovery and drug development. Through its expertise in biosamples, high-throughput genomics technologies and data management and software development, the Company has developed a series of genomic information solutions based on its core product, GeneExpress®. For more information about Gene Logic, visit the Company's Web site at www.genelogic.com or telephone toll-free – 1/800/GENELOGIC.

These statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in this press release. These risks and uncertainties include, but are not limited to, the extent of utilization of genomic information by the pharmaceutical and biotechnology industries in research and product development, our ability to retain existing and obtain additional database customers in a timely manner, risks relating to the development of genomic database products and their use by existing and potential customers and ultimate consumers, our reliance on Affymetrix, Inc. for GeneChip® microarrays and other sole source suppliers, our ability to limit our losses and become profitable, our ability to timely supply customers with customized and new products, continued access to necessary human and animal tissue samples, the impact of technological advances and competition, our ability to enforce our intellectual property rights, and the impact of intellectual property rights of others, as well as other risks and uncertainties included in our Annual Report on Form 10-K for the year ended December 31, 2001 and our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.

Financial tables follow.

- more -

GENE LOGIC INC.
Condensed Statements of Operations
(In thousands, except per share amounts)
(Unaudited)

	Three Months Ended March 31,	
	2002	2001
Revenues	\$ 11,842	\$ 8,211
Expenses:		
Research and development	14,294	15,690
Selling, general and administrative	5,725	4,793
Amortization of goodwill	--	381
Total expenses	20,019	20,864
Loss from operations	(8,177)	(12,653)
Interest (income), net	(839)	(3,286)
Income tax expense	195	49
Net loss before equity in net loss of unconsolidated investee	(7,533)	(9,416)
Equity in net loss of unconsolidated investee	--	(1,189)
Net loss	\$ (7,533)	\$ (10,605)
Net loss per common share, basic and diluted	\$ (0.28)	\$ (0.40)
Shares used in computing basic and diluted per common share	26,833	26,248

GENE LOGIC INC.
Condensed Balance Sheets
(In thousands)

	March 31, 2002	December 31, 2001
	(unaudited)	
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 185,135	\$ 128,273
Marketable securities available-for-sale	--	69,545
Accounts receivable	3,382	2,460
Inventory, net	6,831	6,097
Prepaid expenses	3,157	2,348
Other current assets	1,832	3,512
Total current assets	200,337	212,235
Property and equipment, net	17,994	18,358
Long-term investments	6,021	4,631
Goodwill, net	2,677	2,677
Intangibles and other assets, net	19,742	19,026
Total assets	\$ 246,771	\$ 256,927
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 6,659	\$ 8,479
Accrued expenses	4,162	5,022
Current portion of long-term debt	39	38
Deferred revenue	11,082	11,512
Total current liabilities	21,942	25,051
Deferred revenue	3,749	4,525
Long-term debt	290	300
Other noncurrent liabilities	1,036	1,024
Total liabilities	27,017	30,900
Stockholders' equity:		
Common stock	269	268
Additional paid-in capital	362,343	361,067
Accumulated other comprehensive income	--	17
Accumulated deficit	(142,858)	(135,325)
Total stockholders' equity	219,754	226,027
Total liabilities and stockholders' equity	\$ 246,771	\$ 256,927

#